Literature DB >> 4053272

Nonlinear renal clearance of ultrafilterable platinum in patients treated with cis-dichlorodiammineplatinum (II).

P A Reece, I Stafford, J Russell, P G Gill.   

Abstract

Nonlinear renal clearance of ultrafilterable platinum was observed in 5 of 7 patients given cis-dichlorodiammineplatinum (II) in doses of 50-140 mg/m2 by short-term infusion (2 h). Average renal clearance determined during and 24 h after infusion ranged from 100 to 543 ml/min and always exceeded creatinine clearance, suggesting that ultrafilterable platinum was renally secreted. Saturable tubular reabsorption was postulated on the basis that renal clearance was highest at peak plasma and urinary levels and fell as the levels declined. Although an overall relationship between dose and renal clearance was not apparent, one patient receiving the highest dose (140 mg/m2) had elevated average renal clearance (485 ml/min), probably associated with saturation of reabsorption, whereas a patient receiving 50 mg/m2 had the lowest average renal clearance (100 ml/min), indicating that either active secretion was lower, or tubular reabsorption was saturated. One patient also showed urine-flow-dependent changes in renal clearance. Four patients had transient rises in ultrafilterable platinum levels, which were attributed to changes in renal tubular reabsorption. The results suggest that renal clearance of ultrafilterable platinum is probably dependent on cis-DDP dose, urine flow rate, and individual variability in the extent of active secretion and tubular reabsorption. A sensitive HPLC method was applied and ultrafilterable platinum was detected in the plasma of all patients 24 h after infusion. Renal tubular reabsorption may result in prolonged plasma levels of ultrafilterable platinum, which could contribute to the drug's antitumour effect.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4053272     DOI: 10.1007/BF00263904

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  13 in total

1.  Urine analysis of platinum species derived from cis-dichlorodiammineplatinum(II) by high-performance liquid chromatography following derivatization with sodium diethyldithiocarbamate.

Authors:  S J Bannister; L A Sternson; A J Repta
Journal:  J Chromatogr       Date:  1979-05-21

2.  Renal handling of cis-diamminedichloroplatinum(II).

Authors:  C Jacobs; S M Kalman; M Tretton; M W Weiner
Journal:  Cancer Treat Rep       Date:  1980

3.  Pharmacokinetic evidence for an enterohepatic circulation in a patient treated with cis-dichlorodiammineplatinum (II).

Authors:  J B Vermorken; W J van der Vijgh; H M Pinedo
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1980-05

4.  Kinetics of cis-dichlorodiammineplatinum.

Authors:  P E Gormley; J M Bull; A F LeRoy; R Cysyk
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

5.  The mechanism of renal clearance of cisplatin (cis-dichlorodiammine platinum ii) and its modification by furosemide and probenecid.

Authors:  P T Daley-Yates; D C McBrien
Journal:  Biochem Pharmacol       Date:  1982-07-01       Impact factor: 5.858

6.  Mutagenic activity and identification of excreted platinum in human and rat urine and rat plasma after administration of cisplatin.

Authors:  R Safirstein; M Daye; J B Guttenplan
Journal:  Cancer Lett       Date:  1983-04       Impact factor: 8.679

7.  Mechanisms of renal excretion of cisdichlorodiamine platinum.

Authors:  R Caterson; S Etheredge; P Snitch; G Duggin
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1983-08

8.  Evaluation of reductive amperometric detection in the liquid chromatographic determination of antineoplastic platinum complexes.

Authors:  S J Bannister; L A Sternson; A J Repta
Journal:  J Chromatogr       Date:  1983-04-08

9.  Pharmacokinetic study of cis-dichlorodiammineplatinum(II) (DDP) in the beagle dog: thermodynamic and kinetic behavior of DDP in a biologic millieu.

Authors:  A F LeRoy; R J Lutz; R L Dedrick; C L Litterst; A M Guarino
Journal:  Cancer Treat Rep       Date:  1979-01

10.  Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma.

Authors:  R G Pretorius; N F Hacker; J S Berek; L C Ford; J D Hoeschele; T A Butler; L D Lagasse
Journal:  Cancer Treat Rep       Date:  1983-12
View more
  14 in total

1.  Evaluation of the effect of furosemide on ultrafilterable platinum kinetics in patients treated with cis-diamminedichloroplatinum.

Authors:  M Dumas; C de Gislain; P d'Athis; V Chadoint-Noudeau; A Escousse; J Guerrin; N Autissier
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Predicting tubular reabsorption with a human kidney proximal tubule tissue-on-a-chip and physiologically-based modeling.

Authors:  Courtney Sakolish; Zunwei Chen; Chimeddulam Dalaijamts; Kusumica Mitra; Yina Liu; Tracy Fulton; Terry L Wade; Edward J Kelly; Ivan Rusyn; Weihsueh A Chiu
Journal:  Toxicol In Vitro       Date:  2019-12-17       Impact factor: 3.500

3.  A model for ultrafilterable plasma platinum disposition in patients treated with cisplatin.

Authors:  P A Reece; I Stafford; J Russell; M Khan; P G Gill
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Pharmacokinetics of unchanged carboplatin (CBDCA) in patients with small cell lung carcinoma.

Authors:  P A Reece; J F Bishop; I N Olver; I Stafford; B L Hillcoat; G Morstyn
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2.

Authors:  Giuliano Ciarimboli; Thomas Ludwig; Detlef Lang; Hermann Pavenstädt; Hermann Koepsell; Hans-Jürgen Piechota; Jörg Haier; Ulrich Jaehde; Jochen Zisowsky; Eberhard Schlatter
Journal:  Am J Pathol       Date:  2005-12       Impact factor: 4.307

Review 6.  Xenobiotic transporters and kidney injury.

Authors:  Blessy George; Dahea You; Melanie S Joy; Lauren M Aleksunes
Journal:  Adv Drug Deliv Rev       Date:  2017-01-20       Impact factor: 15.470

7.  Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancer.

Authors:  P A Reece; I Stafford; M Davy; R Morris; S Freeman
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 8.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

Review 9.  Clinical pharmacokinetics of carboplatin.

Authors:  W J van der Vijgh
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

10.  Long-term pharmacokinetic behavior of platinum after cisplatin administration.

Authors:  E Gamelin; P Allain; P Maillart; A Turcant; R Delva; A Lortholary; F Larra
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.